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Abstract
Objectives
Two biomarkers, growth differentiation factor 15 (GDF-15) and fibroblast growth factor 23
(FGF-23)), reflecting different aspects of renal pathophysiology, were evaluated as determi-
nants of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular dis-
ease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D) and
microalbuminuria, but without clinical cardiac disease.
Materials and methods
Prospective study including 200 T2D patients. The predefined endpoint of chronic kidney
disease (CKD) progression: A decline in eGFR of >30% at any time point during follow-up.
Hazard ratios (HR) are provided per 1 SD increment of log2-transformed values.
Results
Mean (± SD) age was 59 ± 9 years, eGFR 91.1 ± 18.3 ml/min/1.73m2 and median (IQR)
UAER 103 (39–230) mg/24-h. During a median 6.1 years follow-up, 40 incident CVD events,
26 deaths and 42 patients reached the CKD endpoint after median 4.9 years. Higher GDF-
15 was a determinant of decline in eGFR >30% and all-cause mortality in adjusted models
(HR 1.7 (1.1–2.5); p = 0.018 and HR 1.9 (1.2–2.9); p = 0.003, respectively). Adding GDF-15
to traditional risk factors improved risk prediction of decline in renal function (relative inte-
grated discrimination improvement (rIDI) = 30%; p = 0.037). Higher FGF-23 was associated
with all-cause mortality in adjusted models (HR 1.6 (1.1–2.2); p = 0.011) with a rIDI of 30%
(p = 0.024).
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Conclusions
In patients with T2D and microalbuminuria, higher GDF-15 and FGF-23 were independently
associated with all-cause mortality and higher GDF-15 improved risk prediction of decline in
kidney function and higher FGF-23 of all-cause mortality, beyond traditional risk factors, but
not independently of GDF-15.
Introduction
Patients with type 2 diabetes (T2D) are at significantly increased risk for both cardiovascular
disease (CVD) and development of chronic kidney disease (CKD)[1]. Diabetic kidney disease
is the most frequent cause of end-stage renal disease (ESRD) in western countries[2]. More-
over, progression of CKD further increases the risk for CVD[3].
Identification of persons at highest risk of rapid progression in CKD would allow stratifica-
tion in an early phase so adequate treatment can be implemented. Currently, presence of albu-
minuria and lower estimated glomerular filtration rate (eGFR) are the best means to identify
persons at highest risk of ESRD[4]. However, the search for additional biomarkers to improve
this stratification is ongoing.
Growth differentiating factor (GDF)-15, a member of the transforming growth factor beta
(TGF-β) cytokine superfamily and the bone-derived hormone fibroblast growth factor (FGF)-
23 are two biomarkers reflecting different aspects of renal pathophysiology. GDF-15 is consid-
ered as a marker of inflammation and oxidative stress and FGF-23 as a regulator of the phos-
phate homeostasis, vitamin D metabolism and bone mineralization. Both biomarkers have
been suggested as risk markers of cardiovascular disease, mortality and decline in renal func-
tion in the general population[5–8], and in patients with CKD[9–15] or CVD[16]. There are
however conflicting results regarding GDF-15 and FGF-23 as predictors of these outcomes in
patients with T2D [15, 17–24].
The aim of the present study was therefore to evaluate if the two biomarkers together or
separately could improve the predictive value for decline in renal function, incident CVD and
all-cause mortality in T2D patients with microalbuminuria, preserved kidney function and no
known cardiac disease.
Materials and methods
Participants and study procedure
In 2007–2008, we enrolled 200 patients with T2D, all Caucasians, from the outpatient clinic at
Steno Diabetes Center Copenhagen, in an observational study. The purpose of this study was
to investigate the prevalence and role of putative asymptomatic coronary artery disease in T2D
patients with microalbuminuria and elevated plasma N-terminal-proBNP levels and/or coro-
nary artery calcium score[25]. The same patients participated in the current prospective fol-
low-up study. The inclusion criteria have been thoroughly described previously [25]. In brief,
patients were eligible if they had T2D according to the WHO criteria, urine albumin excretion
rate (UAER) > 30 mg/24h (two out of three consecutive measurements), normal kidney func-
tion and without any known cardiac disease. All participants received intensive multifactorial
treatment constituting glycaemic, lipid and blood pressure (BP) control, antithrombotic ther-
apy and lifestyle modification. The study complies with the Declaration of Helsinki, was
GDF-15 and FGF-23 in type 2 diabetes
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approved by The Scientific Ethical Committee of the Capital Region of Copenhagen and all
patients gave written informed consent.
Baseline clinical and laboratory measures
Plasma concentrations of FGF-23 and GDF-15 were measured in all patients from samples col-
lected in EDTA tubes and frozen at -80˚C and stored in a research biobank for analysis imme-
diately after the examination of the last participant. Thus, the samples were only thawed once
and the maximal storage time of the samples prior to analysis was 13 months.
Plasma GDF-15 was measured using an immunoassay based on the electro-chemi-lumines-
cence technology (Elecsys 2010)[26]. All measurements of GDF-15 were performed by Roche
Diagnostics (Penzberg, Germany) by investigators blinded to the patient characteristics.
C-terminal FGF-23 concentrations were measured using a second generation enzyme-
linked immunosorbent assay kit (Immunotopics, Inc, San Clemente, CA) with antibodies
directed against two epitopes within the carboxyl-terminal proportion of FGF-23 molecule.
All measurements of FGF-23 were performed at University of Miami (FL, USA).
UAER was measured in 24-h urine collections by an enzyme immunoassay (Vitros, Raritan,
NJ, USA).
Current smoking was defined as one or more cigarettes, cigars or pipes a day. The eGFR
was calculated applying the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation[27]. Retinopathy status was assessed in all patients by fundus photography.
Follow-up
The three predefined endpoints have previously been described [28, 29]. The combined CVD
endpoint was defined as cardiovascular mortality, non-fatal myocardial infarction, stroke,
ischaemic CVD and heart failure. For patients with multiple events, only the first endpoint was
included. Annual measurements of p-creatinine were performed in 177 of the 200 patients as
part of their regular diabetes control at SDCC. The renal endpoint was defined as a decline in
eGFR>30% calculated from the p-creatinine at baseline to the latest available measurement, as
proposed by Coresh et al.[30]. To increase power but also to address the issue of competing
risk we also defined a composite renal endpoint (combining decline in eGFR>30% and all-
cause mortality (as no cases of ESRD were seen).
Information on all patients was traced through the Danish National Death and the Danish
National Health Registries on January 1, 2014. No patients were lost to follow-up. For deceased
patients, information was obtained on the date and cause of death. All deaths were categorized
as CVD unless an unambiguous non-CVD cause was present.
Statistical analyses
Normally distributed variables are presented as means ±standard deviations (SD) and categor-
ical variables as total numbers with corresponding percentages. FGF-23, GDF-15, UACR and
25(OH)-D vitamin were skewed distributed and log2 transformed in all analyses and summa-
rised as medians with interquartile range (IQR). Clinical characteristics of the population at
baseline were compared across the median concentrations of FGF-23 and GDF-15 by use of T-
test for continuous and χ2 test for categorical variables.
Cox proportional hazards analysis was used to compute the hazard ratios (HR) with 95%
confidence intervals (CI) per SD increment. A stepwise approach was applied: Model 1: unad-
justed; Model 2: adjusted for sex, age and p-creatinine; Model 3: adjusted for: sex, age, LDL
cholesterol, smoking, HbA1c, p-creatinine, systolic BP and UACR. The analyses of FGF-23
GDF-15 and FGF-23 in type 2 diabetes
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were additionally adjusted for 25(OH)-D vitamin; and Model 4: Additionally inclusion of
GDF-15 and FGF-23 mutually in the adjusted model.
We applied the Kaplan–Meier failure function to compare the risks of the renal endpoint of
GDF-15 and of all-cause mortality according to the median levels of GDF-15 and FGF-23,
respectively.
To evaluate the incremental contribution of FGF-23 and GDF-15 to standard risk predic-
tion, we calculated the relative integrated discrimination improvement (rIDI), which has been
suggested as a more powerful method to demonstrate the relative contribution of the new bio-
marker for improved risk prediction compared to standard approach [31].
A p-value of<0.05 was considered significant. Statistical analyses were performed using
SAS software (version 9.4, SAS Institute, Cary, NC, USA).
Results
Patient characteristics
The population included 200 patients (76% men) with mean ± SD age of 59±9 years, eGFR
91.1 ± 18.3 ml/min/1.73m2 and median (IQR) UACR 103 (39–230) mg/24h. A total of 120
(60%) had retinopathy. The median FGF-23 and GDF-15 concentrations were 71 (52–108) rel-
ative units/ml and 1533 (1132–2236) ng/l, respectively. Clinical characteristics of the patients,
categorized by the median of GDF-15 and FGF-23 respectively, are shown in Table 1. Patients
with GDF-15 concentrations above the median were older, had longer diabetes duration,
Table 1. Clinical characteristics of the study population at baseline categorized according to growth differentiation factor 15 and fibroblast growth factor 23 below
or above the median.
Growth differentiation factor 15 (μmol/l) P Fibroblast growth factor 23 (RU/ml) P
< 1533 (n = 100)  1533 (n = 100) < 71.29 (n = 100)  71.29 (n = 100)
Male, n (%) 73 (73) 78 (78) 0.41 84 (84) 67 (67) 0.005
Age (years) 55.7 ± 10.0 61.6 ± 2.9 <0.001 59.0 ± 8.8 58.3 ± 8.6 0.55
Known duration of diabetes (years) 14.1 ± 7.7 14.8 ± 7.6 0.012 12.3 ± 7.2 13.2 ± 7.5 0.39
Body mass index (kg/m2) 32.7 ± 5.8 32.4 ± 5.8 0.68 31.6 ± 5.0 33.5 ± 6.3 0.02
HbA1c (%) 7.99 ± 1.44 7.74 ± 1.24 0.19 7.70 ± 1.25 8.02 ± 1.43 0.09
HbA1c (mmol/mol) 64±7.8 61±10 0.19 61±9.8 64±7.9 0.09
Urinary albumin excretion rate (mg/24-h) 116.5(43.0–207.5) 90.0(38.0–318.0) 0.79 107.0(44.0–189.5) 96.0(37.0–161.0) 0.71
P-creatinine (μmol/L) 70.2 ± 15.6 82.7 ± 18.8 <0.001 73.4 ± 16.9 79.5± 19.2 0.019
eGFR (ml/min/1.73m2) 96.5 ± 16.2 82.4 ± 15.5 <0.001 93.1 ± 16.3 85.9 ± 17.7 0.003
25(OH)-D vitamin (nmol/l) 37.1 (21.9–50.1) 36.7 (22.2–53.6) 0.75 37.9 (21.3–58.0) 34.3 (22.2–47.6) 0.52
LDL cholesterol (mmol/L) 1.99 ± 0.84 1.72 ± 0.69 0.015 1.83 ± 0.72 1.86 ± 0.83 0.89
Systolic blood pressure (mmHg) 132 ± 17 129 ± 18 0.29 131 ± 17 129 ± 17 0.50
Current smoker, n (%) 28 (28) 31 (31) 0.64 26 (26) 33 (33) 0.28
Retinopathy, n (%) 59 (59) 61 (61) 0.77 55 (55) 65 (65) 0.15
Treatment with:
Oral antidiabetic, n (%) 79 (79) 91 (91) 0.018 83 (83) 87 (87) 0.43
Insulin, n (%) 60 (60) 64 (64) 0.56 52 (52) 72 (72) 0.004
Antihypertensive drugs, n (%) 99 (99) 99 (99) 1.00 99 (99) 99 (99) 1.00
Statin, n (%) 93 (93) 96 (96) 0.35 94 (94) 95 (95) 0.76
Aspirin, n (%) 91 (91) 92 (92) 0.80 91 (91) 92 (92) 0.80
eGFR: estimated glomerular filtration rate. P-values for differences between participants with Growth differentiation factor 15, and Fibroblast growth factor 23 below or
above the median.
https://doi.org/10.1371/journal.pone.0196634.t001
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lower eGFR and LDL cholesterol and were more frequently treated with oral antidiabetic
drugs than patients with GDF-15 concentrations below the median. Patients with FGF-23 con-
centrations above the median were more frequently men, had higher body mass index, lower
eGFR and were more frequently treated with insulin compared to patients with FGF-23 con-
centrations below the median.
The vast majority of patients were receiving antihypertensive drugs (99%), statins (95%)
and aspirin (90%). Fig 1 illustrates the positive correlation between GDF-15 and FGF-23 (R2 =
0.10; p<0.0001).
Incidence of cardiovascular events, all-cause mortality and decline in eGFR
Median follow-up time was 6.1 (IQR: 5.9–6.6) years. During this period 40 patients experi-
enced a combined CVD endpoint, 26 died and 42 had a decline in eGFR>30%.
The number of composite renal endpoint totalled 55.
The combined CVD endpoint included 11 fatal CVD events (2 cases of acute myocardial
infarction, one case of ischaemic CVD, 6 sudden and otherwise unexplained deaths and 2
cases of heart failure) and 29 non-fatal CVD events (3 cases of acute myocardial infarction, 3
strokes, 19 cases of ischaemic CVD and four cases of heart failure). Of the 26 deaths, 11 were
related to CVD, 9 cancer-related and 6 related to other causes.
The median follow-up for the renal endpoint was 4.9 (IQR: 3.8–5.4) years. In 23 patients
the decline of eGFR>30% was confirmed in two or more measurements, whereas the decline
in eGFR was observed at the last visit in 17 patients without the possibility of confirmation.
None of the patients progressed to ESRD during follow-up.
GDF-15 as a risk marker
Table 2 shows the associations of GDF-15 to the risk of fatal and non-fatal CVD events, all-
cause mortality and decline in eGFR>30% per SD increment. In the unadjusted model higher
GDF-15 concentration was a determinant of CVD events (p = 0.033), all-cause mortality
(p = 0.003) and decline in eGFR>30% (p = 0.018), but only the relation to all-cause mortality
(p = 0.003) and decline in eGFR (p = 0.018) kept significance after adjustment for traditional
Fig 1. Scatterplot illustrating the significant correlation between log2-transformed GDF-15 and FGF-23 concentrations.
https://doi.org/10.1371/journal.pone.0196634.g001
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risk factors. Moreover, GDF-15 remained significant related to risk of all-cause mortality
(p = 0.039) and decline in eGFR>30% (p = 0.013) after additional inclusion of FGF-23 in the
model. Higher GDF-15 was also significantly related to the composite renal endpoint in all
three adjusted models (p0.0019). The rIDI for GDF-15 was 30% (p = 0.037) for decline in
eGFR>30% but was not significant for all-cause mortality (p = 0.077, Table 2).
The cumulative incidence of decline in eGFR>30% and all-cause mortality was higher in
participants with GDF-15 above the median (p0.014; Fig 2, panel a and b) compared to par-
ticipants with GDF-15 below the median.
FGF-23 as a risk marker
Table 2 shows the associations of FGF-23 to the risk of fatal and non-fatal CVD events, all-
cause mortality and decline in eGFR>30% per SD increment. Higher FGF-23 was not signifi-
cantly related to CVD events or decline in eGFR, but was associated with all-cause mortality
both in the unadjusted (p = 0.010) and adjusted (p = 0.011) model. After additional inclusion
of GDF-15 in the model, FGF-23 lost significance (p = 0.16). There was not significant relation
between FGF-23 and the composite renal endpoint (p0.31). The rIDI was 30% (p = 0.024) in
relation to all-cause mortality (Table 2).
The cumulative incidence of all-cause mortality was higher in participants with FGF-23
above the median (p = 0.035; Fig 2, panel c) compared to participants with FGF-23 below the
median.
Table 2. Stepwise Cox regression analyses: Biomarkers in relation to risk of fatal and nonfatal cardiovascular events, all-cause mortality and decline in eGFR>30%
in 200 patients.
Biomarker Model Cardiovascular events
(n = 40)
P All-cause mortality
(n = 26)
P Decline in
eGFR>30%
(n = 42)
P
GDF-15 log
scale
(1 SD = 0.55)
Unadjusted 1.38 (1.03–1.86) 0.033 1.84 (1.32–2.57) 0.0003 1.75 (1.28–2.39) <0.001
Adjusted for sex, age and plasma
creatinine
1.12 (0.78–1.63) 0.54 1.90 (1.31–2.77) 0.0008 1.65 (1.12–2.41) 0.011
Adjusted 1.25 (0.85–1.84) 0.25 1.90 (1.24–2.89) 0.003 1.67 (1.09–2.54) 0.018
Adjusted + FGF-23 1.18 (0.77–1.80) 0.44 1.64 (1.03–2.62) 0.039 1.73 (1.12–2.67) 0.013
rIDI 38.6% 0.08 30.0% 0.04
FGF-23 log
scale
(1 SD = 0.28)
Unadjusted 1.16 (0.86–1.56) 0.33 1.48 (1.10–2.00) 0.010 1.18 (0.88–1.59) 0.27
Adjusted for sex, age and plasma
creatinine
1.23 (0.90–1.68) 0.20 1.55 (1.14–2.10) 0.0047 1.05 (0.75–1.47) 0.77
Adjusted 1.16 (0.81–1.66) 0.41 1.57 (1.11–2.18) 0.011 0.98 (0.68–1.41) 0.90
Adjusted+ GDF-15 1.09 (0.74–1.60) 0.67 1.33 (0.89–1.99) 0.16 0.87 (0.59–1.28) 0.48
rIDI 29.7% 0.02
Number of events given for each endpoint (n =).
Relative integrated discrimination improvement (rIDI): between a model including traditional cardiovascular risk factors only and a model including traditional risk
factors and GDF-15 or FGF-23. GDF-15: growth differentiation factor 15, FGF-23: fibroblast growth factor 23, eGFR: estimated glomerular filtration rate. Values are
hazard ratios with 95% confidence intervals, and represent an SD increment of log-transformed values of the biomarkers.
Adjustment included sex, age, LDL cholesterol, smoking, HbA1c, plasma creatinine, systolic blood pressure and urinary albumin excretion rate. Analyses of fibroblast
growth factor 23 was additionally adjusted for 25(OH)-D vitamin.
https://doi.org/10.1371/journal.pone.0196634.t002
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Discussion
In the present study of patients with T2D, higher GDF-15 independently predicted all-cause
mortality and improved risk prediction of decline in renal function beyond traditional risk fac-
tors. Furthermore, higher FGF-23 independently predicted and improved risk prediction of
all-cause mortality beyond traditional risk factors, but did not keep significance after inclusion
of GDF-15 in the model.
Fig 2. Kaplan-Meier plot of A. GDF-15 in relation to decline in eGFR>30%, B. GDF-15 in relation to all-cause
mortality, C. FGF-23 in relation to all-cause mortality Numbers refer to participants in each category at risk at the
beginning of each 2 year interval. P-values based on log-rank test.
https://doi.org/10.1371/journal.pone.0196634.g002
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GDF-15 as a risk marker
GDF-15 is expressed in various tissues, cells and organs with p53 protein as the direct molecu-
lar target, induced by tissue injury, anoxia and pro-inflammatory cytokines responses[32].
In general, GDF-15 plays a pivotal role in the development and progression of CVD [33]. In
our study of microalbuminuric T2D patients, higher GDF-15 was associated with CVD (event
rate 20%) in unadjusted analyses, but did not predict CVD after adjustment for traditional risk
factors, and in addition predicted all-cause mortality after additional adjustment for FGF-23.
In a study including 861 patients with T2D and advanced nephropathy (mean eGFR 33 ml/
min/1.73m2), no association was found between GDF-15 and the composite CV endpoint
including CV mortality (event rate 12.4%) after adjustment for traditional risk factors compa-
rable to our adjustment[18]. Yet, in another study including 213 T2D patients without albu-
minuria, CKD or CVD, higher GDF-15 did predict CVD in terms of diabetic cardiomyopathy
(event rate 21.1%), but adjustment did not include important risk factors such as BP, lipids,
creatinine and UACR [34]. However, in another study in 746 T2D patients also without albu-
minuria and CKD, Resl et al. found an association between higher GDF-15 and CVD (event
rate 22.9%) even after adjustment for a comprehensive panel of risk factors similar to our
adjustment [20, 35]. In our previous study in 451 patients with T1D and macroalbuminuria
(measured mean GFR 76±33 ml/min/1.72m2), higher levels of GDF-15 predicted CVD and
all-cause mortality. This could not be confirmed in the 440 normoalbuminuric T1D patients,
possibly due to few CVD events (n = 48) [26]. In summary, these studies in T1D and T2D
show conflicting results which partly might be due to differences in kidney function, event
rates and adjustments.
Recently, Nair et al showed higher circulating GDF-15 concentration to be positively corre-
lated with intrarenal expression of GDF-15 and an increased risk of CKD progression in two
independent non-diabetic cohorts with CKD[19]. This indicates a more direct role of GDF-15
in the renal disease process. In our previous as well as present studies in T1D[26] and T2D
respectively, higher GDF-15 predicted decline in renal function beyond traditional risk factors.
This is in accordance with a study of T2D patients with normal renal function, where higher
GDF-15 predicted renal outcome in terms of progression of albuminuria[17]. In T2D patients
with CKD, the renal endpoint including doubling of baseline serum creatinine level, incident
ESRD or a sustained 40% decline in eGFR could also be predicted by higher GDF-15[18].
Thus, these studies suggest that higher GDF-15 is an independent risk marker for renal disease
in T2D from early to late stages of dysfunction.
FGF-23 as a risk marker
FGF-23 is predominantly secreted by osteocytes. It regulates the phosphate homeostasis by
inhibiting the sodium dependent phosphate transporter and thus phosphate reabsorption in
the proximal tubule, hence increasing phosphate excretion. Likewise FGF-23 inhibits 1α-
hydroxylase and thereby the synthesis of 1.25-dihydroxy vitamin D leading to decreased
absorption of phosphate from the gut. Higher FGF-23 is perceived as one of the earliest mark-
ers of kidney disease, reaching very high levels at the time of ESRD[36]. Despite these appar-
ently beneficial physiological effects, increased concentrations of FGF-23 have been linked to
CV events, mortality and initiation of dialysis[7, 8, 10–14]. In our study, higher FGF-23 pre-
dicted all-cause mortality, but did not relate to CVD or decline in renal function. In a previous
analysis of the same population, with a shorter follow-up period (median 3.5 years), we could
not demonstrate any relation either between FGF-23 and yearly decline in eGFR or pro-
gression in albuminuria[24]. Even though the study population had some degree of kidney
involvement in terms of elevated albumin excretion, the kidney function was normal and
GDF-15 and FGF-23 in type 2 diabetes
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median FGF-23 concentration was within the normal range. In contrast, a large community
based study also with FGF-23 concentration within normal range followed for 19 years, dem-
onstrated an association between higher FGF-23 and increased risk of incident ESRD indepen-
dent of kidney function[8]. In a mixed diabetic and non-diabetic cohort of patients with
coronary heart disease, higher FGF-23 predicted CV outcomes in the diabetic but not in the
non-diabetic patients suggesting potential biological differences in the FGF-23 response
between patients with and without diabetes[23].
In T2D, two studies in patients with CKD, higher FGF-23 predicted a decline in renal func-
tion[15, 21]. In another study in T2D, where the majority had normal renal function and 51%
had normoalbuminuria, higher FGF-23 was, like our results, independently associated with
increased risk of all-cause mortality, but was, unlike our findings, also associated to CV out-
come and risk of ESRD [22]. Several factors might explain the observed differences. The popu-
lation included various degrees of diabetic renal disease, where our cohort had more
homogenous renal status, the follow-up time was longer (8–12 years), 13% of the events was
ESRD (n = 48), with no ESRD events in our cohort, and eGFR was calculated based on the
MDRD rather than the CKD-EPI equation, as in our study.
Strength and limitations
The well-defined phenotype of the cohort and no patients lost to follow-up is a strength. The
relative small amount of renal events is a limitation. There are baseline differences regarding
important risk factors for kidney function and mortality. This renders the possibility of resid-
ual confounding, despite correction for these parameters. When investigating development of
decline in renal function, all-cause mortality might be a competing risk. To address this issue,
we defined a composite renal endpoint including decline in renal function and all-cause mor-
tality. We did not have information on the use of vitamin D or calcium supplements, or mea-
sures of phosphate, parathyroid hormone or calcium levels, which might potentially interact
on the FGF-23 concentration[36]. It is however most likely, that our population, due to the
normal kidney function, had normal concentrations of phosphate, parathyroid hormone and
calcium. The definition of kidney function was based upon estimated GFR rather than a more
precise measure[37], such as 51-Chrome-EDTA clearance. The majority of the patients had
diabetic retinopathy indicating that the albuminuria most likely was due to diabetic kidney dis-
ease. However, 40% did not have retinopathy and as diagnostic renal biopsies was not per-
formed; the presence of other non-diabetic renal disease cannot be ruled out.
Clinical implications
Higher GDF-15 remained a significant predictor of all-cause mortality and renal decline after
additional inclusion of FGF-23 in the adjusted model indicating thatGDF-15 is a stronger risk
marker than FGF-23 for these endpoints. This might suggest that there is no added value of
FGF-23 when GDF-15 is measured. However the mechanisms’ underlying the associations
between FGF-23 and GDF-15 on one side and mortality and renal disease on the other re-
mains unclear. Whether higher concentrations of FGF-23 have a detrimental effect on the vas-
culature and kidneys or simply acts as a surrogate marker for presence of cardiac or renal
injury is unsolved. In order to reduce FGF-23 concentrations, interventions should potentially
block or reduce phosphate absorption pharmacologically and/or through reduced dietary
phosphate intake. On a more experimental level biological agents directly targeting or blocking
the actions of FGF-23 in terms of inhibitory anti-FGF-23 antibodies are in development but
without convincing results[38]. Likewise approaches to lower GDF-15, like treatment with
antioxidant or anti-inflammatory agents, may be associated with improved outcome[16].
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Prospective randomized studies of such interventions are needed to clarify if reductions of the
biomarker can translated into improved outcomes before consolidating these markers.
Conclusion
In microalbuminuric T2D patients with normal kidney function and without known cardiac
disease, higher concentration of GDF-15 predicted decline in renal function, CV events and
all-cause mortality. After adjustment for traditional risk factors, the prediction for decline in
renal function and all-cause mortality persisted. Higher FGF-23 concentration was an inde-
pendent risk marker for all-cause mortality, but was no longer significant after inclusion of
GDF-15 in the model. Higher GDF-15 was a risk marker for the renal endpoint and all-cause
mortality independently of the level of FGF-23.
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